Neil P. Shah

Statistics

Publications

Citations

13.4K

H-Index

Active since

2004

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

University of California, San Francisco

Bristol-Myers Squibb (United States)

Jena University Hospital

South Australia Pathology

Neil P. Shah is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and chronic myeloid leukemia therapy.

ORCID

Publications per year

2004–2024

Publications

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2006 · 1.8K citations · Full text

Medicine, Hematology, Pharmacology +15

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Hagop M. Kantarjian, Neil P. Shah, Andreas Hochhaus et al. · New England Journal of Medicine · 2010 · 1.6K citations

Medicine, Pharmacology, Pharmacotherapy +10

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

Jörge E. Cortes, Giuseppe Saglio, Hagop M. Kantarjian et al. · Journal of Clinical Oncology · 2016 · 946 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, Hagop M. Kantarjian, Neil P. Shah et al. · New England Journal of Medicine · 2012 · 770 citations · Full text

Medicine, Oncology, Pharmacology +13

Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

Kathryn G. Roberts, Ryan D. Morin, Jinghui Zhang et al. · Cancer Cell · 2012 · 718 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16

1–5 of 43